Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...

As thousands of Chinese families take DNA tests, the results are upending what adoptees abroad thought they knew about their ...

A 23AndMe spokesperson told Bloomberg that the website delays were due to heavy site traffic. This comes in the wake of the company's weekend bankruptcy filing. In other news: McCormick begins ...

Most of 23andMe bought for a lot more than one could have thought–and why? Yesterday, the board of 23andMe confirmed that they have a court-approved definitive agreement for the sale of their core ...

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

Me has faced an uncertain future after struggles to find a profitable business model and privacy concerns related to ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

The once-popular genetic testing company will be acquired by Regeneron after filing for bankruptcy, but the questions about ...

Regeneron's win at action means the bankrupt firm's popular DNA-testing service can continue — along with a privacy policy ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug discovery.

Regeneron to acquire nearly all of 23andMe’s assets for $256M, marking a new chapter for the direct-to-consumer genetic testing pioneer.